GET DAILY SIGNALSDanaher (DHR): Weighing the Path to a $260 Price Target and +14% Upside
Key Takeaways
- The central stock price target used here is $260, the arithmetic mean of recently verified analyst price targets, implying roughly 14% upside from the latest close of $227.97.
- Roughly two dozen analyst targets were reviewed, spanning a wide range from about $195 to $310, reflecting genuine disagreement over Danaher's valuation and growth trajectory.
- The strongest supports are a recovering bioprocessing market, steady diagnostics growth, accretive M&A, and strong free cash flow generation.
- The biggest risks are a premium valuation, respiratory-testing headwinds, China pricing pressure, and cautious near-term guidance from new leadership.
- Readers can explore Danaher's Major News, Today's Price Move, Forecast, and Earnings pages for additional context and updates.
- For automated, AI-driven monitoring of this and other names, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Danaher Corporation (DHR) is a global science and technology company operating across Life Sciences, Diagnostics, and Biotechnology. It is a stock, not an ETF, and carries broad sell-side coverage. After its third-quarter 2026 report, several firms raised targets: TD Cowen moved to $270, Goldman Sachs to $275, J.P. Morgan to $270, Stifel to $260, Citi to $270, and Baird to $254. Older targets include Morgan Stanley at $255, Jefferies at $265, UBS at $250, Barclays at $230, and more cautious marks from Wells Fargo at $195, Guggenheim at $200, and RBC Capital at $215.
The arithmetic mean of the verified individual targets lands near $259, which rounds to a central target of $260. The full range is unusually wide — roughly $195 to $310 — so the "average analyst price target" should be read as a midpoint of divergent views, not a guarantee. Bullish analysts emphasize a bioprocessing recovery and diagnostics momentum, while cautious ones point to a premium multiple and uneven near-term demand. Note that these figures are an internal calculation of individual targets, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Danaher closed at $227.97, roughly 6% below its 52-week high of $242.80 and well above its 52-week low of $160.93. Reaching $260 would require a gain of about 14% — a substantial move by the standards of a large-cap with a market capitalization above $160 billion and a trailing P/E near 38x.
The company's most recent quarter showed revenue up about 8% year over year and EPS up roughly 38%, a beat that nonetheless triggered a "sell the news" reaction after management offered conservative commentary on near-term growth. The path toward $260 would likely depend on sustained core revenue growth across bioprocessing and diagnostics, plus multiple stability rather than further valuation compression.
What Could Support a Move Toward the Target
- Bioprocessing recovery: Life sciences demand has shown sequential acceleration, a key earnings driver for the company's largest growth engine.
- Diagnostics growth: Cepheid's non-respiratory molecular assays are growing at a low-double-digit to mid-teens pace, supporting steadier recurring revenue.
- M&A catalysts: The Masimo transaction closed and is accretive, and the StatLab acquisition was announced, adding to the growth runway.
- Cash generation and capital returns: Strong free cash flow and share repurchases provide support to per-share metrics.
- AI and innovation: Management has flagged AI-enabled drug discovery and an AI Lab initiative as long-term growth catalysts.
What Could Prevent the Target From Being Reached
- Premium valuation: A trailing P/E near 38x leaves limited room for error if growth decelerates; a reset toward peer multiples would weigh on the share price.
- Respiratory-testing headwinds: Declining COVID-era respiratory demand remains a drag on diagnostics results.
- China and academic funding: Pricing pressure in China and soft academic budgets could temper life sciences growth.
- Timing of bioprocessing shipments: Management noted more than $100 million of shipments pushed into the following year, adding uncertainty.
- New leadership and guidance reset: A new chief executive's conservative forward outlook could cap sentiment until execution is proven.
Technical Levels and Market Structure
Danaher trades near the top of its 52-week range, with the $242.80 high acting as the most immediate resistance level. A decisive break above that prior high would clear a meaningful hurdle on the way toward $260. On the downside, the stock remains above its longer-term moving averages — the 60-day average near $215 is a widely watched support level — while $200 represents a psychological floor that coincides with several cautious analyst targets. From what I see, these levels provide useful context when evaluating the risk-reward profile.
Time Horizon and What Investors Should Monitor
Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms differ in methodology and timing. Investors should watch the next earnings release and guidance updates, revisions to analyst estimates following bioprocessing order trends, any commentary on China and respiratory testing, interest-rate decisions that affect valuation multiples, and progress on the Masimo and StatLab integrations. None of these items offers a definitive forecast, but each can shift the market outlook materially. I'm watching this closely as the next few quarters unfold.
Final Assessment
Can DHR reach $260? The target represents a roughly 14% advance from $227.97 and sits near the midpoint of a wide analyst range of about $195 to $310. Reaching it would likely require a sustained bioprocessing recovery, continued diagnostics momentum, and valuation multiples holding near current elevated levels. The principal obstacles are a premium P/E, respiratory and China-related headwinds, and cautious guidance from new leadership. The outcome is genuinely contested: bullish and cautious analysts diverge by more than $100 on the stock's fair value. The target is a reasonable reference point, not a certainty, and investors should track earnings, guidance, and estimate revisions as the clearest near-term signals.
Monitoring with AI Tools
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a practical way to track shifts in market conditions for names like DHR. The system applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and broader trends. It serves as a useful complement to traditional fundamental work when following Danaher or the healthcare tools sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
Momentum Indicator for DHR turns positive, indicating new upward trend
DHR saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 52 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 108 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 13 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.048) is normal, around the industry mean (65.876). P/E Ratio (40.420) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of industrial instruments and machinery
Industry MedicalSpecialties
Advertisement